

## Special Issue

# Implantable Cardioverter Defibrillator (ICD) in Cardiac Disease

### Message from the Guest Editor

Novel medical therapies and new interventional approaches to cardiac disease have currently changed our medical approach to patients with heart disease. However, the risk of ventricular arrhythmias and sudden cardiac death (SCD) are still a key element that every physician need to face in their patients. We set up this Special Issue in order to highlight new scientific development on risk stratification and prevention of sudden cardiac death. Therefore, for this Special Issue, we would like to select papers regarding new methodologies for risk stratification of sudden cardiac death, new insights on the use of implantable Cardioverter Defibrillator (ICD) and future approaches to the prevention of SCD.

---

### Guest Editor

Dr. Cristina Balla

Cardiology Department, University Hospital S. Anna Ferrara, 44121 Ferrara, Italy

---

### Deadline for manuscript submissions

closed (15 July 2024)



## Journal of Cardiovascular Development and Disease

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.3  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/si/166546](https://mdpi.com/si/166546)

*Journal of Cardiovascular  
Development and Disease*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcdd@mdpi.com](mailto:jcdd@mdpi.com)

[mdpi.com/journal/  
jcdd](https://mdpi.com/journal/jcdd)





# Journal of Cardiovascular Development and Disease

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.3  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/journal/  
jcdd](https://mdpi.com/journal/jcdd)



## About the Journal

### Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease* (JCDD, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to JCDD undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. JCDD guarantees fast dissemination of results to a large scientific audience

---

### Editor-in-Chief

Prof. Dr. Thomas Brand  
National Heart & Lung Institute, Imperial College London, South  
Kensington Campus, London SW7 2AZ, UK

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) /  
CiteScore - Q2 (General Pharmacology, Toxicology and  
Pharmaceutics)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 28.8 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).